I have a question for the board. Dalton told June
Post# of 85558
Although the remark is somewhat ambiguous, it did get me to think about what that reason might be, and that is especially true if the accountants and attorneys are done with the financials. What I came up with is this. Suppose AGRiMED bought out Univec? If AGRiMED still had much they wanted to do before going public, but still wanted the UNVC transdermal patch, then why not?
I am not saying this would be the best long term path for UNVC shareholders, but if we received a fair market price, this transaction could happen fairly quickly. This action would allow AGRiMED to remain secretive about their operations, and they could continue to develop and market the patch.
Just throwing this thought out there.